Related references
Note: Only part of the references are listed.Utilization and Expenditure of Anti-cancer Medicines in Kosovo: Findings and Implications
Arianit Jakupi et al.
PHARMACOECONOMICS-OPEN (2018)
Cancer risks in Nairobi (2000-2014) by ethnic group
Anne Korir et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
Raising the Dose and Raising the Cost: The Case of Pembrolizumab in Lung Cancer
Peter B. Bach et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
A global comparison of the cost of patented cancer drugs in relation to global differences in wealth
Daniel A. Goldstein et al.
ONCOTARGET (2017)
Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13
Courtney Davis et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13
Courtney Davis et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Raising the Dose and Raising the Cost: The Case of Pembrolizumab in Lung Cancer
Peter B. Bach et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Prescription patterns and adequacy of blood pressure control among adult hypertensive patients in Kenya; findings and implications
Jennifer M. Mbui et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2017)
Economic analysis of the Nairobi Cancer Registry: Implications for expanding and enhancing cancer registration in Kenya
Anne Korir et al.
CANCER EPIDEMIOLOGY (2016)
Generic oncology drugs: are they all safe?
Y. Tony Yang et al.
LANCET ONCOLOGY (2016)
Target prices for mass production of tyrosine kinase inhibitors for global cancer treatment
Andrew Hill et al.
BMJ OPEN (2016)
Challenging Perceptions About Oncology Product Pricing in Breast and Colorectal Cancer
Anthony Barron et al.
PHARMACEUTICAL MEDICINE (2016)
Global Cancer Statistics, 2012
Lindsey A. Torre et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
Incidence of cancer in Nairobi, Kenya (2004-2008)
Anne Korir et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Pricing in the Market for Anticancer Drugs
David H. Howard et al.
JOURNAL OF ECONOMIC PERSPECTIVES (2015)
Delivering maximum clinical benefit at an affordable price: engaging stakeholders in cancer care
Ronan J. Kelly et al.
LANCET ONCOLOGY (2014)
Evidence-informed frameworks for cost-effective cancer care and prevention in low, middle, and high-income countries
Kalipso Chalkidou et al.
LANCET ONCOLOGY (2014)
Variation in charges for 10 common blood tests in California hospitals: a cross-sectional analysis
Renee Y. Hsia et al.
BMJ OPEN (2014)
Dispelling the myths around cancer care delivery: It's not all about costs
Carin A. Uyl-de Groot et al.
JOURNAL OF CANCER POLICY (2014)
Full Disclosure - Out-of-Pocket Costs as Side Effects
Peter A. Ubel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Global burden of cancers attributable to infections in 2008: a review and synthetic analysis
Catherine de Martel et al.
LANCET ONCOLOGY (2012)
Viewing the Kenyan health system through an equity lens: implications for universal coverage
Jane Chuma et al.
INTERNATIONAL JOURNAL FOR EQUITY IN HEALTH (2011)
Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis
A. Cameron et al.
LANCET (2009)
Assessing the economic burden of breast cancer in a US managed care population
John J. Barron et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Share Paper
